IEG Policy is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tate & Lyle submits allulose clinical trial in support of FDA labeling petition

Study shows allulose not linked to dental caries

This article is powered by Food Chemical News

Tate & Lyle Ingredients Americas LLC says a clinical trial that shows allulose does not operate as a sugar and lead to tooth decay is another reason why FDA should exempt the low-calorie sweetener from being included as a carbohydrate, sugar or added sugar on the Nutrition Facts label.

Advertisement

Related Content

FDA petitioned to change label for low-calorie sugar substitute allulose

Topics

What to read next

UsernamePublicRestriction

Register

PL217465

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel